---
document_datetime: 2023-12-13 14:29:11
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/vantobra-previously-tobramycin-pari-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: vantobra-previously-tobramycin-pari-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.9184358
conversion_datetime: 2025-12-23 06:34:25.962422
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Vantobra

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                          | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                      |
|----------------------|------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0010              | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 14/10/2023                          |                                             | SmPC                             |                                                                                                                                                                              |
| R/0009               | Renewal of the marketing authorisation.                                                        | 20/07/2023                          | 15/09/2023                                  | SmPC and PL                      | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Vantobra in the approved indication remains favourable and |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                                                                                               |            |            |             | therefore recommended the renewal of the marketing authorisation with unlimited validity.                                                  |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10370 /202209 | Periodic Safety Update EU Single assessment - tobramycin (nebuliser solution) (centrally authorised product only)                                                                                                                                                                                                                                                             | 25/05/2023 | 26/07/2023 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10370/202209. |
| IA/0007/G           | This was an application for a group of variations. B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer | 09/02/2022 | n/a        |             |                                                                                                                                            |
| PSUSA/10370 /202009 | Periodic Safety Update EU Single assessment - tobramycin (nebuliser solution) (centrally authorised product only)                                                                                                                                                                                                                                                             | 09/04/2021 | n/a        |             | PRAC Recommendation - maintenance                                                                                                          |
| IB/0006             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                | 12/01/2021 | 04/02/2022 | SmPC and PL |                                                                                                                                            |
| PSUSA/10370 /201909 | Periodic Safety Update EU Single assessment - tobramycin (nebuliser solution) (centrally authorised product only)                                                                                                                                                                                                                                                             | 17/04/2020 | n/a        |             | PRAC Recommendation - maintenance                                                                                                          |
| IA/0002             | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                   | 27/09/2019 | n/a        |             |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| IAIN/0001   | A.2.a - Administrative change - Change in the (invented) name of the medicinal product for CAPs   | 12/04/2019   | 04/02/2022   | SmPC, Labelling and PL   |
|-------------|---------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|